Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) PT at $52.29
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price […]
More Stories
Optivise Advisory Services LLC Buys New Position in iShares 3-7 Year Treasury Bond ETF (NASDAQ:IEI)
Optivise Advisory Services LLC bought a new stake in shares of iShares 3-7 Year Treasury Bond ETF (NASDAQ:IEI – Free...
Great Valley Advisor Group Inc. Acquires 370,107 Shares of Janus Henderson AAA CLO ETF (NYSEARCA:JAAA)
Great Valley Advisor Group Inc. raised its holdings in shares of Janus Henderson AAA CLO ETF (NYSEARCA:JAAA – Free Report)...
JPMorgan Ultra-Short Income ETF (NYSEARCA:JPST) Shares Purchased by Great Valley Advisor Group Inc.
Great Valley Advisor Group Inc. grew its position in shares of JPMorgan Ultra-Short Income ETF (NYSEARCA:JPST – Free Report) by...
Flagstar Advisors Inc. Increases Stake in First Trust Senior Loan ETF (NASDAQ:FTSL)
Flagstar Advisors Inc. lifted its position in First Trust Senior Loan ETF (NASDAQ:FTSL – Free Report) by 5.7% in the...
Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells $16,440.78 in Stock
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) CEO Howard W. Robin sold 16,278 shares of the firm’s stock in a...
T-Mobile US, Inc. (NASDAQ:TMUS) Shares Acquired by First Horizon Advisors Inc.
First Horizon Advisors Inc. increased its stake in shares of T-Mobile US, Inc. (NASDAQ:TMUS – Free Report) by 8.9% in...